Method for Obtaining Xeno-Free Hbs Cell line

• US 20100129906A1
• Filed: 10/06/2006
• Published: 05/27/2010
• Est. Priority Date: 10/07/2005
• Status: Abandoned Application

• Current Assignee: Cellartis AB
• Original Assignee: Cellartis AB
• Inventors: Frej, Katarina, Semb, Henrik, Kilmare, Eva Karin, Ellerström, Catharina, Hyllner, Sven Johan, Strehl, Raimund, Moya, Karina
• Application Number:
  US12/083,192
• Publication Number:
  US 20100129906A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2502/13 connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
• CPC Class Codes: C12N 2502/1323 Adult fibroblasts
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0656 Adult fibroblasts

Abstract

A method for obtaining a stable xeno-free hBS cell line, xeno-free hBS cell lines obtained according to said method and use thereof. The method comprises the steps of:

• • i) removing the zona pellucida from a blastocyst to obtain trophectoderm-enclosed inner cell mass by a xeno-free procedure,
  • ii) at least partly removing the trophectoderm to obtain isolated inner cell mass cells by a xeno-free procedure,
  • iii) placing the inner cell mass cells on a layer of human feeder cells in a xeno-free medium,
  • iv) co-culturing of the inner cell mass cells with human feeder cells for a time period of from about 5 days to about 50 days in a xeno-free medium,
  • v) releasing the inner cell mass cells or cells derived thereof from trophectoderm overgrowth, if any, by a xeno-free procedure,
  • vi) selectively, transferring the inner cell mass cells or cells derived thereof to a fresh layer of human feeder cells in a xeno-free medium to obtain xeno-free hBS cells,
  • vii) propagating the xeno-free hBS cells by co-culturing with human feeder cells in a xeno-free medium to obtain a xeno-free hBS cell line.

The xeno-free hBS cell line is suitable for use in medicine and in in vitro testing.

Claims

1. A method for obtaining a xeno-free hBS cell line, the method comprising the steps of:

i) removing the zona pellucida from a blastocyst to obtain trophectoderm-enclosed inner cell mass by a xeno-free procedure,

ii) at least partly removing the trophectoderm to obtain isolated inner cell mass cells by a xeno-free procedure,

iii) placing the inner cell mass cells on a layer of human feeder cells in a xeno-free medium,

iv) co-culturing of the inner cell mass cells with human feeder cells for a time period of from about 5 days to about 50 days in a xeno-free medium,

v) releasing the inner cell mass cells or cells derived thereof from trophectoderm overgrowth, if any, by a xeno-free procedure,

vi) selectively, transferring the inner cell mass cells or cells derived thereof to a fresh layer of human feeder cells in a xeno-free medium to obtain xeno-free hBS cells, and

vii) propagating the xeno-free hBS cells by co-culturing with human feeder cells in a xeno-free medium to obtain a xeno-free hBS cell line.

2. A method according to claim 1 further comprising a step:

viii) propagating the xeno-free hBS cell line by co-culturing with feeder human cells in a xeno-free medium and passaging the cells at a suitable time intervals ranging from about 2 days to about 20 days.

3. A method according to claim 1 comprising a step:

ix) transferring the xeno-free hBS cell line to a xeno-free and feeder free culture system comprising a suitable xeno-free support matrix and a xeno-free medium.

4. A method according to claim 1, wherein step i) is performed by using a) an acidic solution, b) one or more recombinant enzymes, or c) a mechanical procedure.

5. A method according to claim 4, wherein step i) is performed by using an acidic solution.

6. A method according to claim 5, wherein step i) is performed by subjecting the blastocyst to the acidic solution for about 5 seconds to about 180 seconds.

7. A method according to claim 5, wherein the pH of the acidic solution is from about 2 to about 3.

8. A method according to claim 5, wherein the acidic solution is Acid Tyrodes solution.

9. A method according to claim 1, wherein step ii) is performed by using a) an acidic solution, b) one or more recombinant enzymes, or c) a mechanical procedure.

10. A method according to claim 9, wherein step ii) is performed by using an acidic solution.

11. A method according to claim 10, wherein step ii) is performed by subjecting the trophectoderm-enclosed inner cell mass obtained in step i) to the acidic solution for about 5 seconds to about 180 seconds.

12. A method according to or claim 10, wherein the pH of the acidic solution is from about 2 to about 3.

13. A method according to claim 10, wherein the acidic solution is Acid Tyrodes solution.

14. A method according to claim 9, wherein step ii) is performed by using one or more recombinant enzymes.

15. A method according to claim 14, wherein the one ore more recombinant enzymes are recombinant proteolytic enzymes.

16. A method according to claim 15, wherein the one or more recombinant proteolytic enzymes are selected from the group consisting of recombinant trypsin and TrypLE™

Select.

17. A method according to claim 14, wherein step ii) is performed by subjecting the trophectoderm-enclosed inner cell mass obtained in step i) to from about 5.000 U to about 10.000 U of recombinant trypsin for from about 0.5 minutes to about 30 minutes.

18. A method according to claim 14, wherein step ii) is performed by subjecting the trophectoderm-enclosed inner cell mass obtained in step i) to an undiluted ready-to-use concentration of TrypLE™

Select for from about 0.5 to about 10 minutes.

19. A method according to claim 1, wherein the time period in step iv) is from about 5 days to about 30 days in step iv).

20. A method according to claim 1, wherein one or more medium changes are performed during the co-cultivation of the inner cell mass cells in step iv) by changing from about 20% to about 100%.

21. A method according to claim 1, wherein one or more medium changes are performed during the co-cultivation of the inner cell mass cells in step iv) by changing about 50% of the medium.

22. A method according to claim 20, wherein the one or more medium changes are performed at time intervals of from about 2 days to about 14 days.

23. A method according to claim 1, wherein the inner cell mass cells or cells derived thereof are released from trophectoderm overgrowth, if any, by using a mechanical procedure in step v).

24. A method according to claim 23, wherein the mechanical procedure comprises using glass capillaries as a cutting tool.

25. A method according to claim 1, wherein the inner cell mass cells or cells derived thereof are released from trophectoderm overgrowth, if any, by using one or more recombinant enzymes in step v).

26. A method according to claim 25, wherein the one or more recombinant enzymes are recombinant proteolytic enzymes.

27. A method according to claim 26, wherein the one or more proteolytic enzymes are selected from the group consisting of recombinant trypsin and TrypLE™

Select.

28. A method according to claim 25 wherein step v) is performed by incubating the inner cell mass cells or cells derived thereof with from about 5.000 U to about 10.000 U of recombinant trypsin for from about 0.5 minutes to about 30 minutes.

29. A method according to claim 25, wherein step v) is performed by incubating the inner cell mass cells or cells derived thereof with an undiluted ready-to-use concentration of TrypLE™

Select for from about 0.5 minutes to about 15 minutes.

30. A method according to claim 1, wherein one or more passages are performed during the propagation of the xeno-free hBS cells in step vii).

32. A method according to claim 30, wherein passage is performed by using a mechanical procedure.

33. A method according to claim 30, wherein passage is performed by using one or more recombinant enzymes.

34. A method according to claim 33, wherein the one or more recombinant enzymes are selected from the group consisting of TrypLE™

Select, recombinant trypsin and recombinant collagenase.

35. A method according to claim 33, wherein step vii) is performed by using from about 5.000 U to about 10.000 U of recombinant trypsin for from about 0.5 minutes to about 30 minutes.

36. A method according to claim 33, wherein step vii) is performed by using an undiluted ready-to-use concentration of TrypLE™

Select for from about 0.5 minute to about 15 minutes.

37. A method according to claim 33, wherein step vii) is performed by using about 200 U/ml recombinant collagenase for from about 1 minute to about 40 minutes.

38. A method according to claim 1, wherein the passage of cells in step viii) is performed by mechanical dissection.

39. A method according to claim 38, wherein the mechanical dissection is performed by using a glass capillary as cutting tool.

40. A method according to claim 2, wherein the passage of cells in step viii) is performed using one or more recombinant enzymes.

41. A method according to claim 40, wherein the one or more recombinant enzymes are selected from the group consisting of TrypLE™

Select, recombinant trypsin and recombinant collagenase.

42. A method according to claim 40, wherein step viii) is performed by using from about 5.000 U to about 10.000 U of recombinant trypsin for from about 0.5 minutes to about 30 minutes.

43. A method according to claim 40, wherein step viii) is performed by using an undiluted ready-to-use concentration of TrypLE™

Select for from about 0.5 minute to about 15 minutes.

44. A method according to claim 40, wherein step viii) is performed by using about 200 U/ml recombinant collagenase for from about 1 minute to about 40 minutes.

45. A method according to claim 3, wherein the xeno-free support matrix used in step ix) can be selected from the group consisting of recombinant human gelatin, recombinant human fibronectin, human placental extracellular matrix.

46. A method according to claim 3, wherein the xeno-free medium used in step ix) can be the same or different from the xeno-free medium employed in any of steps iii), iv), vi), vii) and viii).

47. A method according to claim 3, wherein the xeno-free medium used in step ix) can be conditioned by human feeder cells or it can be supplemented with suitable factors to maintain undifferentiated growth.

48. A method according to claim 47, wherein the suitable factors can be selected from the group consisting of recombinant bFGF and activators of the WNT pathway.

49. A method according to claim 2, wherein the human feeder cells used in any of steps iii), iv), vi), vii) and viii) are obtained under xeno-free conditions.

50. A method according to claim 49, wherein the human feeder cells are derived from healthy human tissue.

51. A method according to claim 49, wherein the human feeder cells are dermal fibroblasts derived from neonatal human foreskin.

52. A method according to claim 2, wherein the xeno-free medium used in any of the steps iii), iv), vi), vii) and/or viii) comprises a base medium suitable for propagation of human inner cell mass cells.

53. A method according to claim 52, wherein the base medium is DMEM.

54. A method according to claim 52, wherein the xeno-free medium further comprises from about 2 ng/ml to about 100 ng/ml recombinant bFGF.

55. A method according to claim 52, wherein the xeno-free medium further comprises 10 ng/ml recombinant bFGF.

56. A method according to claim 52, wherein the xeno-free medium further comprises from about 1% v/v to about 30% v/v human serum.

57. A method according to claim 52, wherein the xeno-free medium further comprises 20% v/v human serum.

58. A method according to claim 2, wherein the human serum used in any of steps iii), iv), vi), vii) and viii) is prepared by the following steps

a) collecting healthy human blood in not-heparin coated bags,

b) agitating the not-heparin coated bags for a time period of from about 0.5 hours to about 5 hours.

c) incubating the not-heparin coated bags at a temperature of at the most 5°

C. for a time period of at least 10 hours,

d) optionally, selection based on clotting quality,

e) separating the serum from the clotted material,

f) sterile filtrating the serum obtained in step d),

g) pooling serum from at least 15 donors, and

h) freezing serum before use.

61. A xeno-free hBS cell line obtained by a method as defined in claim 1.

62. A xeno-free hBS cell line according to claim 61, which has never been directly or indirectly exposed to any non-human animal material.

63. A xeno-free hBS cell line according to 62, wherein any organic material used is of human origin or is synthetic, semi-synthetic or recombinant material.

64. A xeno-free hBS cell line according to claim 61, wherein the animal is a mammal.

65. A xeno-free hBS cell line according to claim 61 displaying at least one of the following criteria;

positive reactions for Oct-4, TRA-1-60, TRA-1-81, SSEA-3 and/or SSEA-4 and negative reaction for SSEA-1.

66. A method for preparation of differentiated derivatives. of a xeno-free hBS cell line comprising utilizing the zeno-free hBS cell line of claim 61.

68. A medicinal product for the prevention and/or treatment of pathologies and/or diseases caused by-tissue degeneration comprising an effective concentration of a xeno-free hBS cell line obtained by the method of claim 1 or a differentiated derivative thereof.

69. A medicinal product for the treatment and/or prevention of metabolic pathologies and/or diseases comprising an effective concentration of a xeno-free hBS cell line obtained by the method of claim 1 or a differentiated derivative thereof.

71. A method for studying human degenerative diseases comprising utilizing a xeno-free hBS cell line obtained by the method of claim 1 or a differentiated derivative thereof.

72. A drug discovery process comprising utilizing a xeno-free hBS cell line obtained by the method of claim 1 or a differentiated derivative thereof.

73. A method for in vitro toxicity testing comprising utilizing a xeno-free hBS cell line obtained by the method of claim 1 or a differentiated derivative thereof.

31. A method according to step 30, wherein hBS cells are selectively passaged.

59. A method for obtaining a xeno-free hBS cell line, the method comprising the steps of:

1) removing the zona pellucida and at least a part of the trophectoderm from a blastocyst by incubation of the blastocyst with Acid Tyrodes Solution for a time period of from about 10 sec to about 10 min at room temperature to obtain isolated inner cell mass cells,

2) placing the inner cell mass cells on a layer of human foreskin fibroblast feeder cells in a xeno-free medium comprising DMEM, human serum, recombinant bFGF, L-glutamine or glutamax, non-essential amino acids, β

-mercaptoethanol, penicillin and streptomycin,

3) co-culturing of the inner cell mass cells with human foreskin fibroblast feeder cells in a xeno-free medium for a time period of from about 5 days to about 15 days changing at least 50% of the xeno-free medium every 3-5 days,

4) releasing the inner cell mass cells or cells derived thereof from trophectoderm overgrowth, if any, by using TrypLE™

Select (Invitrogen) as enzymatic treatment,

5) selectively, transferring the inner cell mass cells or cells derived thereof to fresh layers of human foreskin fibroblast feeder cells in a xeno-free medium to obtain xeno-free hBS cells,

6) propagating the xeno-free hBS cells by co-culturing with human foreskin fibroblast feeder cells in a xeno-free medium to obtain a xeno-free hBS cell line.

60. A method according to claim 59 further comprising a steppropagating the xeno-free hBS cell line by co-culturing with human foreskin fibroblast feeder cells in a xeno-free medium, changing at least 50% of the xeno-free medium every 3-5 days and passaging the cells at a suitable time interval.

67. (canceled)

70. (canceled)

74. (canceled)